Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.

Anthony R. Mato,Jeff P. Sharman,Juliana Biondo,Mei Wu,Yong Mun,Su Young Kim,Kathryn Humphrey,Michelle Boyer,Qian Zhu,John F. Seymour

Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.

2020

Anthony R. Mato
Jeff P. Sharman
Juliana Biondo
Mei Wu
Yong Mun
Su Young Kim
Kathryn Humphrey
Michelle Boyer
Qian Zhu
John F. Seymour

8028Background: Ven + rituximab (VenR) has a manageable safety profile and improves survival in patients (pts) with R/R CLL, but discontinuation/interruption is frequent. We present new data from t...

Keywords:

Oncology
Chronic lymphocytic leukemia
Discontinuation
Ven
Venetoclax
Internal medicine
Pathology
relapsed refractory
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations